KRRO
Korro Bio, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$167.45M
P/E Ratio
—
EPS
$-11.68
Beta
2.23
52W High
$55.89
52W Low
$5.20
50-Day MA
$12.28
200-Day MA
$18.42
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $3.84M |
| Gross Profit (TTM) | $-45.40M |
| EBITDA | $-79.32M |
| Operating Margin | -2154.00% |
| Return on Equity | -87.80% |
| Return on Assets | -26.80% |
| Revenue/Share (TTM) | $0.39 |
| Book Value | $8.29 |
| Price-to-Book | 1.41 |
| Price-to-Sales (TTM) | 43.58 |
| EV/Revenue | 25.36 |
| EV/EBITDA | -5.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -43.10% |
| Shares Outstanding | $14.42M |
| Float | $9.36M |
| % Insiders | 0.57% |
| % Institutions | 100.64% |
Historical Volatility
HV 10-Day
105.71%
HV 20-Day
86.36%
HV 30-Day
81.21%
HV 60-Day
83.98%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($19.89 target)
2
Strong Buy5
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026